Dosing to rash: A phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503)
- J. R. Brahmer
- , J. W. Lee
- , A. M. Traynor
- , M. M. Hidalgo
- , J. M. Kolesar
- , J. M. Siegfried
- , P. P. Guaglianone
- , J. D. Patel
- , M. D. Keppen
- , J. H. Schiller
Research output: Contribution to journal › Article › peer-review
24
Scopus
citations